# Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy

Study · id `cardio:ct-nct01239004` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01239004](<https://clinicaltrials.gov/study/NCT01239004>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01239004

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 140 participants.

## Technical summary

Registry record NCT01239004. Randomized; quadruple masking; primary purpose prevention. Start 2010-11 (registry gives no type); primary completion 2011-08 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 140 participants (enrolled count; ClinicalTrials.gov record NCT01239004, source copy `cardio:ctgov-nct01239004-2012-01-06`, retrieved 2026-10-31)
- Start date: 2010-11 (registry gives no type) (ClinicalTrials.gov record NCT01239004, source copy `cardio:ctgov-nct01239004-2012-01-06`, retrieved 2026-10-31)
- Primary completion: 2011-08 (actual) (ClinicalTrials.gov record NCT01239004, source copy `cardio:ctgov-nct01239004-2012-01-06`, retrieved 2026-10-31)
- Completion: 2011-08 (actual) (ClinicalTrials.gov record NCT01239004, source copy `cardio:ctgov-nct01239004-2012-01-06`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT01239004, source copy `cardio:ctgov-nct01239004-2012-01-06`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01239004-2012-01-06`, retrieved 2026-10-31)

## The registry's words

- Brief title: Colesevelam Treatment for Impaired Fasting Glucose During Niacin Therapy
- Acronym: CERTAIN
- Condition: Dyslipidemia
- Condition: Hyperlipidemia
- Condition: Hyperglycemia
- Intervention (Drug): Placebo
- Intervention (Drug): Colesevelam
- Lead sponsor: Radiant Research
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)

## Provenance

Content hash: 4ca54d639b643673268980a96af1fe2ee4f5889fb94d093ddd34f97fda6a1363
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
